Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT)

By afschroeder • July 23, 2026

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin Y, Cai L, Chaudhry AA, Remorino A, Stewart R, Luciani-Silverman L, Miller K, Dellamonica D, Faria J, Zhang Y. Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). Clin Cancer Res. 2026 Jul 22. doi: 10.1158/1078-0432.CCR-25-3729. Epub ahead of print. PMID: 42485106.

Tags: Hematology/Oncology, Publications

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]

Interference of Clonal Hematopoiesis in cfDNA Liquid Biopsy Testing & Identification of Actionable Alterations in Large Diverse Cohort of US Veterans

Valle LF, Scobie M, Rowe K, Pritchard CC, Montgomery B, Garraway IP, Nickols NG, Schoen MW, Kishan AU, Kelley MJ, Rettig MB, Maxwell KN. Interference[...]